No Data
No Data
Earnings Preview: RIGL to Report Financial Results Post-market on May 06
Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update
Express News | Rigel Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Rigel Pharmaceuticals, Inc. Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Benign Growth For Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Underpins Stock's 26% Plummet
Express News | Rigel Announces Settlement Agreement Resolving Tavalisse® (Fostamatinib Disodium Hexahydrate) Patent Litigation